Jun
2026
Shanghai New International Expo Center
Visit us
stand N6B61, Packaging & Drug Delivery
Cryoport Systems LLC
Exhibitor at CPHI & PMEC China 2026
About Us
Categories
-
Country/Region:United States
-
On CPHI since:2026
-
Certificates:1
-
Employees:500 - 999
Company types
Event information
CPHI & PMEC China 2026
-
16 Jun 2026 - 18 Jun 2026
-
Shanghai New International Expo Center
-
Visit us at stand N6B61, Packaging & Drug Delivery
Products Featured at CPHI & PMEC China 2026
-
Product BioServices & Biostorage
Cryoport Systems’ BioServices offering is designed to provide comprehensive and compliant support for the unique needs of biologics and advanced therapy development and commercialization. Our services extend beyond logistics to encompass critical elements such as biostorage, kit production, secondary packa... -
Product Consulting & Advisory Services
Cryoport Systems’ Consulting & Advisory Services are designed to provide life sciences organizations with unparalleled expertise and support across their temperature-controlled supply chain. Our team of industry-leading experts partners with you to create high-quality, compliant solutions that address ... -
Product IntegriCell® Cryopreservation Services
IntegriCell® cryopreservation services from Cryoport Systems optimize leukapheresis-derived cell therapies by enhancing the safety, quality, and viability of manufacture-ready cryopreserved leukopaks. Our state-of-the-art cryopreservation process, integrated with our end-to-end global temperature-controlle... -
Product Logistics & Shipping Systems
Cryoport Systems offers the industry’s most advanced temperature-controlled shipping solutions, designed specifically for the unique requirements of the life sciences. Whether you’re moving cellular starting material, high-value biologics, or finished therapies, our integrated systems protect your commodit...
Cryoport Systems LLC Resources (1)
-
Brochure IntegriCell Cryopreservation Services
IntegriCell® cryopreservation services from Cryoport Systems optimize leukapheresis-derived cell therapies by enhancing the safety, quality, and viability of manufacture-ready cryopreserved leukopaks.



